Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
Public ClinicalTrials.gov record NCT03371355. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver fat in participants with hypertriglyceridemia, Type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD).
Study identification
- NCT ID
- NCT03371355
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 105 participants
Conditions and interventions
Interventions
- Placebo Drug
- ISIS 703802 40 mg Drug
- ISIS 703802 80 mg Drug
- ISIS 703802 20 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2017 (Actual)
- Primary completion
- Nov 21, 2019 (Actual)
- Completion
- Feb 24, 2020 (Actual)
- Last update posted
- Feb 1, 2021
2017 – 2020
United States locations
- U.S. sites
- 38
- U.S. states
- 14
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Sites | Chandler | Arizona | 85224 | — |
| Clinical Site | Fountain Hills | Arizona | 85268 | — |
| Clinical Site | Glendale | Arizona | 85306 | — |
| Clinical Site | Mesa | Arizona | 85206 | — |
| Clinical Site | Mesa | Arizona | 85213 | — |
| Clinical Site | Phoenix | Arizona | 85020 | — |
| Clinical Site | Phoenix | Arizona | 85023 | — |
| Clinical Site | Phoenix | Arizona | 85050 | — |
| Clinical Site | Huntington Park | California | 90255 | — |
| Clinical Site | Los Angeles | California | 90057 | — |
| Clinical Site | Montclair | California | 91710 | — |
| Clinical Site | Panorama City | California | 91402 | — |
| Clinical Site | Poway | California | 92064 | — |
| Clinical Site | Boca Raton | Florida | 33487 | — |
| Clinical Site | Jensen Beach | Florida | 34957 | — |
| Clinical Site | Jupiter | Florida | 33458 | — |
| Clinical Site | Miami | Florida | 33165 | — |
| Clinical Site | Port Saint Lucie | Florida | 34952 | — |
| Clinical Site | Atlanta | Georgia | 30328 | — |
| Clinical Site | Chicago | Illinois | 60640 | — |
| Clinical Site | Indianapolis | Indiana | 46260 | — |
| Clinical Site | Louisville | Kentucky | 40213 | — |
| Clinical Site | Edina | Minnesota | 55435 | — |
| Clinical Site | Bridgeton | New Jersey | 08302 | — |
| Clinical Site | Princeton | New Jersey | 08540 | — |
| Clinical Site | Greensboro | North Carolina | 27410 | — |
| Clinical Site | High Point | North Carolina | 27265 | — |
| Clinical Site | Cincinnati | Ohio | 45219 | — |
| Clinical Site | Cincinnati | Ohio | 45227 | — |
| Clinical Site | Charleston | South Carolina | 29407 | — |
| Clinical Site | Austin | Texas | 78735 | — |
| Clinical Site | Carrollton | Texas | 75010 | — |
| Clinical Site | Dallas | Texas | 75234 | — |
| Clinical Site | Houston | Texas | 77058 | — |
| Clinical Site | Hurst | Texas | 76054 | — |
| Clinical Site | San Antonio | Texas | 78215 | — |
| Clinical Site | San Antonio | Texas | 78229 | — |
| Clinical Site | Layton | Utah | 84041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03371355, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03371355 live on ClinicalTrials.gov.